Mialgin

Pethidine hydrochloride, the active ingredient in Mialgin, is an opioid analgesic presented as a sterile solution for intramuscular, intravenous, and subcutaneous use. It is employed to manage moderate to severe pain, including postoperative pain, in adult patients requiring rapid analgesia.

GNH USA supplies Mialgin as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance across all markets. Our distribution network adheres to stringent handling standards to maintain product integrity from manufacture to end‑user.

Pethidine hydrochloride is an opioid analgesic that acts on the central nervous system to relieve pain. - Moderate to severe acute pain: provides rapid analgesia for intense pain episodes. - Postoperative pain: reduces pain following surgical procedures. - Trauma‑related pain: alleviates pain associated with injuries and emergency care.

Pethidine hydrochloride may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea - Vomiting - Dizziness - Drowsiness - Constipation - Sweating

Serious or Rare Side Effects: - Respiratory depression - Severe hypotension - Seizures - Allergic reactions (rash, itching, anaphylaxis) - Adrenal insufficiency - Cardiac arrhythmias

When using pethidine hydrochloride, several precautions should be observed to ensure patient safety. - Respiratory assessment: monitor breathing rate and depth, especially in opioid‑naïve patients. - Dependence risk: evaluate for signs of tolerance or addiction with prolonged use. - Renal/hepatic impairment: adjust dosing or avoid use in severe organ dysfunction. - Hypersensitivity: discontinue if any allergic reaction such as rash or swelling occurs. - Elderly patients: start with lower doses and monitor closely for sedation. - Store at ambient temperature: keep in original container, protect from moisture and light.

Pethidine hydrochloride can interact with other medicines, influencing its efficacy or safety.

Major Interactions (Avoid): - Central nervous system depressants (e.g., benzodiazepines, alcohol): may cause profound respiratory depression. - Monoamine oxidase inhibitors (MAOIs): increase risk of serotonin syndrome. - Other opioids: additive sedative and respiratory effects. - Respiratory depressants (e.g., barbiturates): heightened risk of life‑threatening breathing suppression.

Moderate Interactions (Monitor Closely): - CYP3A4 inhibitors (e.g., erythromycin, ketoconazole): may raise pethidine plasma levels. - Diuretics: can enhance hypotensive effects. - Antihistamines: may increase sedation. - Certain antidepressants (e.g., SSRIs): monitor for serotonin syndrome signs.